Please assess the completion status of the following clinical trial:

Trial Title: Epidural Morphine for Postoperative Analgesia After Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (age of 18 years or older);~* American Society of Anesthesiologists classification I-III;~* Scheduled to undergo unilateral TKA under combined spinal and epidural anesthesia.~Exclusion Criteria:~* Age higher than 90 years old;~* Presence of any contraindication to neuraxial block or peripheral nerve block;~* Continuous use of opioid analgesics during the last month;~* Unable to understand Numeric Rating Scale for pain evaluation or existence of language barrier;~* Severe renal insufficiency (requirement of renal replacement therapy);~* History of asthma;~* Recruited in another clinical trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Epidural morphine (Type: EXPERIMENTAL): 1. Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.~2. Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~3. Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h.
- Epidural placebo (Type: PLACEBO_COMPARATOR): 1. Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.~2. Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~3. Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h.

Based on this trial design, predict the completion outcome and termination type (if applicable).